Van Lanschot Kempen Investment Management N.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Van Lanschot Kempen Investment Management N.V. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,318 shares of the biopharmaceutical company's stock after selling 954 shares during the quarter. Van Lanschot Kempen Investment Management N.V.'s holdings in Regeneron Pharmaceuticals were worth $3,788,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $6,364,000. Morse Asset Management Inc grew its position in Regeneron Pharmaceuticals by 0.9% in the third quarter. Morse Asset Management Inc now owns 4,807 shares of the biopharmaceutical company's stock worth $5,053,000 after acquiring an additional 43 shares in the last quarter. Anchor Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 212.0% during the third quarter. Anchor Investment Management LLC now owns 858 shares of the biopharmaceutical company's stock worth $902,000 after acquiring an additional 583 shares during the last quarter. Sculati Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 1.9% during the third quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company's stock valued at $1,970,000 after purchasing an additional 38 shares during the period. Finally, Pine Valley Investments Ltd Liability Co lifted its stake in shares of Regeneron Pharmaceuticals by 19.0% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company's stock valued at $5,575,000 after purchasing an additional 848 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.5 %

REGN traded up $2.88 on Friday, hitting $602.64. The company had a trading volume of 964,377 shares, compared to its average volume of 723,191. The stock has a market capitalization of $65.88 billion, a price-to-earnings ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44. The stock has a fifty day moving average price of $638.93 and a 200-day moving average price of $728.60. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $11.86 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Analysts Set New Price Targets

Several research firms have recently weighed in on REGN. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Bernstein Bank cut their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.